...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergology international: official journal of the Japanese Society of Allergology >Drug-induced hypersensitivity syndrome in Japan in the past 10 years based on data from the relief system of the Pharmaceuticals and Medical Devices Agency
【24h】

Drug-induced hypersensitivity syndrome in Japan in the past 10 years based on data from the relief system of the Pharmaceuticals and Medical Devices Agency

机译：根据药品和医疗器械局的救济系统得出的数据，日本过去10年的药物诱发的超敏反应综合征

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Drug-induced hypersensitivity syndrome (DIHS) is characterized by a limited number of causal drugs, delayed onset, worsening of clinical symptoms after discontinuation of the causal drugs, sequential reactivations of several herpesviruses, and development of several organ system failures long after clinical resolution.1, 2 The causal drugs of DIHS include carmabazepine, phenytoin, phenobarbital, zonisamide, mexiletine, diaphenylsulfone (dapson), salazosulfapyridine and allopurinol.2, 3 The data of DIHS have been collected to date mostly by referring to published article or meeting abstracts. Japan has a relief system for sufferers from adverse drug reactions (ADRs) managed by the Pharmaceuticals and Medical Devices Agency (PMDA) which provides relief benefits for patients with severe ADRs in the appropriate use of the drugs concerned.4 In recent years the proportion of DIHS among cutaneous ADRs has significantly increased probably because this type of ADR has become well known.5 We analyzed the open data on DIHS patients from the relief system of the PMDA during a 10-year period (http://www.pmda.go.jp/relief-services/index.html) and elucidated the recent trend of this ADR. The χ2-test was used to analyze the data, and p < 0.05 was considered statistically significant.
机译：药物诱发的超敏反应综合征（DIHS）的特点是：因果药物数量有限，起因延迟，因果药物停用后临床症状恶化，几种疱疹病毒的顺序重新激活以及在临床解决后很长一段时间内出现的几种器官系统衰竭。 1，2 DIHS的致病药物包括卡马西平，苯妥英钠，苯巴比妥，zonisamide，美西律，二苯砜（dapson），salazosulfapyridine和别嘌呤醇。2，3迄今为止，DIHS的数据主要通过参考已发表的文章或会议摘要来收集。日本拥有由药品和医疗器械局（PMDA）管理的针对药物不良反应（ADR）的患者的救济制度，该制度可为患有严重ADR的患者合理使用相关药物提供救济。4皮肤ADR中的DIHS显着增加，可能是因为这种类型的ADR已广为人知。5我们分析了10年间来自PMDA缓解系统的DIHS患者公开数据（http：//www.pmda.go （.jp / relief-services / index.html），并阐明了该ADR的最新趋势。 χ2检验用于分析数据，p <0.05被认为具有统计学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号